If you’re considering medical support to manage weight and blood sugar, you’ve likely heard of semaglutide and tirzepatide. These are the active ingredients in drugs like Ozempic® and Mounjaro®. But while these GLP-1 medications share similar mechanisms and purposes, they aren’t identical. 

This guide breaks down semaglutide versus tirzepatide: how each works, their side effects, and how to access them.

How semaglutide and tirzepatide work

Both semaglutide and tirzepatide are prescription medications that mimic a hormone called glucagon-like peptide-1 (GLP-1). GLP-1 keeps food in your stomach longer and tells the satiety centers in your brain to think about food less. It also triggers insulin release while lowering glucagon, another hormone that would otherwise push blood sugar up. 

Semaglutide binds to GLP-1 receptors and activates that entire process with much longer-lasting effects. That way, it reduces the calories you eat and improves blood sugar control.

So, how is tirzepatide different from semaglutide? Tirzepatide activates two hormonal pathways instead of one. It targets the receptors of GLP-1 as well as those of glucose-dependent insulinotropic polypeptide (GIP). GIP helps your body respond to insulin more effectively and plays a role in how you store and use energy from food. 

In head-to-head clinical trials, the combined action of GLP-1 and GIP translated into greater average weight loss with tirzepatide than with semaglutide. We’ll explore this comparison in depth below.

FDA approvals and indications: What each drug is cleared for

FDA approval for semaglutide and tirzepatide varies by brand, dose, and medical use. Here’s what each is cleared for.

Semaglutide

• Ozempic®: Weekly injection or daily pill for type 2 diabetes
• Rybelsus®: Daily pill for type 2 diabetes
• Wegovy®: Weekly injection or daily pill approved for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol; also authorized for cardiovascular risk reduction in adults with heart disease and a BMI over 27, and for MASH, a type of fatty liver disease linked to metabolic dysfunction

Tirzepatide

• Mounjaro®: Weekly injection for type 2 diabetes
• Zepbound®: Weekly injection for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition; also approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

Semaglutide vs. tirzepatide side effects

Because both medications act on GLP-1 receptors, they share a similar side effect profile. Digestive reactions (like nausea and decreased appetite) are the most common. These tend to peak with each dose raise and ease as your body adjusts.

In the SURMOUNT-5 trial—a head-to-head comparison trial of these two drugs—overall adverse event rates were similar. And serious adverse events were uncommon in both groups (4.8% with tirzepatide, 3.5% with semaglutide).

But one finding stood out: People taking semaglutide were more than twice as likely to stop treatment because of digestive side effects (5.6%) than those on tirzepatide (2.7%). Preclinical research suggests that GIP activation may have a protective, anti-nausea effect. This could explain why tirzepatide was better tolerated despite targeting an additional receptor. 

The table below shows how often specific reactions were reported in each drug’s FDA approval trials. Because these come from separate studies with different patient populations (not from SURMOUNT-5), they aren’t a direct comparison, but they give a useful sense of what to expect on each medication. 

Semaglutide vs. tirzepatide for weight loss: What clinical trials show

SURMOUNT-5 was the first trial to compare semaglutide to tirzepatide for weight loss directly. Over 72 weeks, people on tirzepatide lost an average of 20% of their body weight, compared with nearly 14% on semaglutide. Waist circumference also dropped by 18.4 cm with tirzepatide versus 13.0 cm with semaglutide. And blood pressure, triglycerides, and fasting insulin all improved more with tirzepatide as well.

Real-world data paints a similar picture. A retrospective study of U.S. electronic health records found that at six months, people on tirzepatide lost about 11% of their body weight versus roughly 9% on semaglutide. Results tend to be more modest in real-world studies because patients miss doses and don’t have the structured support of a clinical trial.

The difference between tirzepatide and semaglutide is clear with scientific evidence. The effectiveness gap may be smaller or larger depending on research design, but the data typically favors tirzepatide. Individual results depend on your condition at starting treatment, the dose you tolerate, and the lifestyle changes you make alongside treatment.

Cost and access for ongoing treatment

Because both semaglutide and tirzepatide work best as long-term treatments, consistent access matters as much as which drug you start. Out-of-pocket costs depend on your insurance plan, your dose, and which savings programs you qualify for.

At list price, both drugs run roughly $1,100 to $1,350 per month. But most people don’t pay this price. Here’s how Wegovy® and Zepbound® compare on cost through their main access paths:

The most common insurance barriers are prior authorizations, step therapy requirements, and employer plan exclusions for weight management drugs. If your plan denies coverage, your provider can often appeal or help you explore alternatives.

Which medication is right for you? Maven Clinic can help

Tirzepatide produces more weight loss on average and may be easier to tolerate. Semaglutide comes in both injection and pill form and has a longer track record. The right choice depends on your health history, insurance coverage, and how your body responds to treatment.

A Maven Clinic GLP-1 Care specialist can help you choose a medication and support you throughout treatment. Learn more and start your journey today. 

FAQ

Can you switch from semaglutide to tirzepatide?

Yes—in a study published in Endocrine Practice, people who switched directly from a GLP-1 treatment (including semaglutide) to tirzepatide at 5 mg saw improved blood sugar control and additional weight loss within 12 weeks, with milder digestive side effects that typically seen in patients starting tirzepatide for the first time.

But note that these drugs shouldn’t be taken at the same time. Stop one before starting the other.

How long does it take to see results on semaglutide vs. tirzepatide?

You don’t have to reach a full maintenance dose to start seeing results. Weight loss begins during dose escalation, with noticeable changes typically within the first 12 weeks. In SURMOUNT-5, tirzepatide showed a faster early weight loss trajectory than semaglutide.

Which GLP-1 medication is better for women over 40?

No clinical trials have compared these drugs specifically in women over 40, but the existing evidence highlights different strengths that matter for this age group. Semaglutide may be a stronger fit if cardiovascular health is a priority. It’s also available as a daily pill, which some women prefer over weekly injections. Tirzepatide may appeal if weight loss or blood sugar control is the primary goal.